Kennedy Capital Management LLC Buys 5,251 Shares of Stryker Co. (NYSE:SYK)

Kennedy Capital Management LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 116.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,753 shares of the medical technology company's stock after purchasing an additional 5,251 shares during the quarter. Kennedy Capital Management LLC's holdings in Stryker were worth $3,512,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Morse Asset Management Inc raised its stake in shares of Stryker by 16.5% during the third quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company's stock worth $509,000 after acquiring an additional 200 shares in the last quarter. Sunbelt Securities Inc. raised its stake in shares of Stryker by 25.6% during the third quarter. Sunbelt Securities Inc. now owns 501 shares of the medical technology company's stock valued at $181,000 after acquiring an additional 102 shares during the last quarter. World Investment Advisors LLC grew its stake in shares of Stryker by 126.1% in the third quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company's stock worth $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Arvest Bank Trust Division purchased a new position in Stryker during the 3rd quarter valued at about $245,000. Finally, Wilmington Savings Fund Society FSB raised its position in Stryker by 13.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company's stock valued at $16,183,000 after purchasing an additional 5,361 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

SYK has been the topic of several research analyst reports. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Finally, Needham & Company LLC restated a "buy" rating and issued a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $423.05.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Performance

NYSE:SYK traded down $6.54 during trading hours on Tuesday, reaching $346.88. The company had a trading volume of 1,670,378 shares, compared to its average volume of 1,361,566. The firm has a market cap of $132.40 billion, a price-to-earnings ratio of 44.70, a PEG ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm's 50 day moving average price is $373.64 and its 200-day moving average price is $373.40. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. On average, analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. Stryker's dividend payout ratio (DPR) is 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.